News

RBM is an emerging area which gives endless opportunities to explore, transform, and evolve.

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

2018 has been an exciting year in the clinical trials industry, as we have seen many changes in novel concepts, and the evolution of some concepts to the point where initiatives and pilots are crystalizing into common practice.

Updated employee announcements, business news, awards, and recognition in the industry today.

As the risks grow of a disorderly UK withdrawal from the European Union, the warnings about what could go wrong for the supply of medicines in Europe become ever louder.

In the following Q&A, Guillaume Marquis-Gravel, MD, and Kevin Monroe discuss the advancements and related challenges of incorporating new technological tools in drug development, including eClinical approaches currently undertaken in the foundation’s own studies.

To further streamline product development and facilitate post market safety surveillance, the agency has developed a new Framework for Real-World Evidence that spells out opportunities and concerns in advancing these approaches.

This eBook will focus on advancing research, drug development, and trial management in rare diseases. Articles cover considerations from virtual trials and eCOA to the case for highly-skilled CRAs.

As the use of PRO expands in clinical trials, ePRO vendors themselveshave expanded beyond this constrained definition. Increasingly, the use of eCOA is being used to encompass all data collected related to the patient, which includes PRO, clinician reported (ClinRO) and observer or caregiver reported outcomes (ObsRO). Further, with mobile health technology use growing in general healthcare, that use is changing outcomes data collection in clinical trials. This e-Book tackles the changing world of PRO collection in clinical trials.

Applied Clinical Trials presents the latest issues that have risen to prominence since RBM adoption grows. This edition presents a well-rounded look at RBM including articles that describe current RBM trends; a survey of European CRAs, which shows the difficulties among sites and monitors with RBM; a comprehensive look at how sponsors and CROs can support their employees in the RBM transition, and closes with a case study on Novartis' use of adaptive monitoring.

Oncology remains the therapeutic area with the most drug failures, the lowest numbers of patients enrolled and the highest with the number of drugs in clinical trials. Many trends in oncology clinical trials seek to address these challenges and include the use of biomarkers, immunotherapies, and adaptive designs.

Translational medicine; bench-to-bedside; agile development. All these terms use updated processes, new technologies and data to inform decisions earlier in clinical development. Supported by expedited regulatory pathways, which require extensive safety monitoring to accompany these earlier approvals, has made the gaps between preclinical and clinical a looming reality.

Have the roles of the monitor advanced? How are CRAs accepting the change? How is pharma implementing RBM-is it more remote, centralized or a combination? How important is eSource to RBM? This eBook will highlight articles that answer these question.

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways.